Tonix Pharmaceuticals Holding Corp. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

SUBSEQUENT EVENTS (Details Narrative)

SUBSEQUENT EVENTS (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended	2 Months Ended	3 Months Ended	12 Months Ended
	Mar. 18, 2020	Feb. 25, 2020	Feb. 07, 2020	Nov. 14, 2019	Feb. 28, 2020	Mar. 31, 2020	Mar. 23, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of options granted								95,517	10,206
Exercise price (in dollars price per share)								$ 21.74	$ 375.15
Proceeds from the exercise of warrants								$ 70
Underwriting Agreement [Member] \| Alliance Global Partners [Member]
Percentage of underwriting discount				7.00%
Offering expenses				$ 500
Subsequent Event [Member]
Net proceeds							$ 29,000
Subsequent Event [Member] \| Warrants from Feb 7 Financing [Member]
Number of exercised warrants						10,800,000
Exercised price (in dollars per share)						$ 0.57
Proceeds from the exercise of warrants						$ 6,200
Subsequent Event [Member] \| Warrants from Nov 2019 Financing [Member]
Number of exercised warrants						2,300,000
Exercised price (in dollars per share)			$ 0.57			$ 0.57
Proceeds from the exercise of warrants						$ 1,300
Subsequent Event [Member] \| Series B Convertible Preferred Stock [Member]
Number of shares converted (in shares)					5,313
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Alliance Global Partners [Member]
Sale of stock, price (in dollars per share)					$ 1.10
Percentage of underwriting discount					7.00%
Underwriting discount					$ 1,100
Net proceeds					14,800
Offering expenses					$ 100
Number of shares issued (in shares)					14,550,000
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Alliance Global Partners [Member] \| Public Offering [Member]
Percentage of underwriting discount			7.00%
Underwriting discount			$ 500
Net proceeds			6,700
Offering expenses			$ 300
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Class A Unit [Member]
Number of units sold			3,837,000
Sale of stock, price (in dollars per share)			$ 0.57
Subsequent Event [Member] \| Underwriting Agreement [Member] \| Class B Unit [Member]
Number of units sold			5,313
Sale of stock, price (in dollars per share)			$ 1,000
Conversion price (in dollars per share)			$ 0.57
Number of shares of common stock convertible			1,754.386
Number of warrants issued			1,754.386
Exercised price (in dollars per share)			$ 0.57
Warrant term			5 years
Subsequent Event [Member] \| Southern Research Institute Collaboration [Member]
Research collaboration	$ 1,300
Subsequent Event [Member] \| Exercise Price $0.40 [Member]
Number of options granted		343,500
Exercise price (in dollars price per share)		$ 0.40
Exercisable term		10 years
Subsequent Event [Member] \| Exercise Price $0.40 [Member] \| Vesting 12 Months from Grant Date [Member]
Vesting percentage		33.33%
Vesting period		12 months
Subsequent Event [Member] \| Exercise Price $0.40 [Member] \| Vesting Monthly Thereafter [Member]
Vesting percentage		2.78%
Vesting period		24 months
Subsequent Event [Member] \| Exercise Price $0.50 [Member]
Number of options granted		207,000
Exercise price (in dollars price per share)		$ 0.50
Exercisable term		10 years
Subsequent Event [Member] \| Exercise Price $0.50 [Member] \| Vesting 12 Months from Grant Date [Member]
Vesting percentage		33.33%
Vesting period		12 months
Subsequent Event [Member] \| Exercise Price $0.50 [Member] \| Vesting Monthly Thereafter [Member]
Vesting percentage		2.78%
Vesting period		24 months